Matthew N. Newmeyer

Matthew N. Newmeyer

Auto-generated profile, based on publicly available information

Matthew N. Newmeyer

Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
MNMatthew N Newmeyer
Matthew N Newmeyer
MSMadeleine J Swortwood
Madeleine J Swortwood
ABAllan J Barnes
Allan J Barnes
OAOsama A Abulseoud
Osama A Abulseoud
KSKarl B Scheidweiler
Karl B Scheidweiler
MHMarilyn A Huestis
Marilyn A Huestis
BACKGROUND: There is increasing interest in markers of recent cannabis use because following frequent cannabis intake, Δ9-tetrahydrocannabinol (THC) may be detected in blood for up to 30 days. The minor cannabinoids cannabidiol, cannabinol (CBN), and THC-glucuronide were previously detected for ≤2.1 h in frequent and occasional smokers' blood after cannabis smoking. Cannabigerol (CBG), Δ9-tetrahydrocannabivarin (THCV), and 11-nor-9-carboxy-THCV might also be recent use markers, but their blood pharmacokinetics have not been investigated. Additionally, while smoking is the most common administration route, vaporization and edibles are frequently used.METHODS: We characterized blood pharmacokinetics of THC, its phase I and phase II glucuronide metabolites, and minor cannabinoids in occasional and frequent cannabis smokers for 54 (occasional) and 72 (frequent) hours after controlled smoked, vaporized, and oral cannabis administration.RESULTS: Few differences were observed between smoked and vaporized blood cannabinoid pharmacokinetics, while significantly greater 11-nor-9-carboxy-THC (THCCOOH) and THCCOOH-glucuronide concentrations occurred following oral cannabis. CBG and CBN were frequently identified after inhalation routes with short detection windows, but not detected following oral dosing. Implementation of a combined THC ≥5 μg/L plus THCCOOH/11-hydroxy-THC ratio <20 cutoff produced detection windows <8 h after all routes for frequent smokers; no occasional smoker was positive 1.5 h or 12 h following inhaled or oral cannabis, respectively.CONCLUSIONS: Vaporization and smoking provide comparable cannabinoid delivery. CBG and CBN are recent-use cannabis markers after cannabis inhalation, but their absence does not exclude recent use. Multiple, complimentary criteria should be implemented in conjunction with impairment observations to improve interpretation of cannabinoid tests. Clinicaltrials.gov Identifier: NCT02177513

19 September 2016 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
MSMadeleine J. Swortwood
Madeleine J. Swortwood
MNMatthew N. Newmeyer
Matthew N. Newmeyer
MAMaria Andersson
Maria Andersson
OAOsama A. Abulseoud
Osama A. Abulseoud
KSKarl B. Scheidweiler
Karl B. Scheidweiler
MHMarilyn A. Huestis
Marilyn A. Huestis

19 February 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
Mehdi FarokhniaMehdi Farokhnia
Mehdi Farokhnia
GMGray R. McDiarmid
Gray R. McDiarmid
MNMatthew N. Newmeyer
Matthew N. Newmeyer
VMVikas Munjal
Vikas Munjal
OAOsama A. Abulseoud
Osama A. Abulseoud
LLLorenzo Leggio
Lorenzo Leggio
As perspectives on cannabis continue to shift, understanding the physiological and behavioral effects of cannabis use is of paramount importance. Previous data suggest that cannabis use influences food intake, appetite, and metabolism, yet human research in this regard remains scant. The present study investigated the effects of cannabis administration, via different routes, on peripheral concentrations of appetitive and metabolic hormones in a sample of cannabis users. This was a randomized, crossover, double-blind, placebo-controlled study. Twenty participants underwent four experimental sessions during which oral cannabis, smoked cannabis, vaporized cannabis, or placebo was administered. Active compounds contained 6.9 ± 0.95% (~50.6 mg) ∆9-tetrahydrocannabinol (THC). Repeated blood samples were obtained, and the following endocrine markers were measured: total ghrelin, acyl-ghrelin, leptin, glucagon-like peptide-1 (GLP-1), and insulin. Results showed a significant drug main effect (p = 0.001), as well as a significant drug × time-point interaction effect (p = 0.01) on insulin. The spike in blood insulin concentrations observed under the placebo condition (probably due to the intake of brownie) was blunted by cannabis administration. A significant drug main effect (p = 0.001), as well as a trend-level drug × time-point interaction effect (p = 0.08) was also detected for GLP-1, suggesting that GLP-1 concentrations were lower under cannabis, compared to the placebo condition. Finally, a significant drug main effect (p = 0.01) was found for total ghrelin, suggesting that total ghrelin concentrations during the oral cannabis session were higher than the smoked and vaporized cannabis sessions. In conclusion, cannabis administration in this study modulated blood concentrations of some appetitive and metabolic hormones, chiefly insulin, in cannabis users. Understanding the mechanisms underpinning these effects may provide additional information on the cross-talk between cannabinoids and physiological pathways related to appetite and metabolism.

5 October 2021 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
MTMina W. Tehrani
Mina W. Tehrani
MNMatthew N. Newmeyer
Matthew N. Newmeyer
Ana  RuleAna Rule
Ana Rule
JUJohns University
Johns University

1 June 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MNMatthew N. Newmeyer
Matthew N. Newmeyer
MSMadeleine J. Swortwood
Madeleine J. Swortwood
OAOsama A. Abulseoud
Osama A. Abulseoud
MHMarilyn Ann Huestis
Marilyn Ann Huestis

1 July 2016 in Journal of Chromatography A
Verified
Journal Article
Closed access
KSKarl B. Scheidweiler
Karl B. Scheidweiler
MNMatthew N. Newmeyer
Matthew N. Newmeyer
ABAllan J. Barnes
Allan J. Barnes
MHMarilyn A. Huestis
Marilyn A. Huestis